

Identifying and developing next-generation therapies that aim to significantly improve the lives of patients

RTW Biotech Opportunities Ltd (the “Company” or LSE: RTW) is an investment fund focused on identifying transformative assets across the life sciences sector. Our approach is driven by applying deep scientific and commercial expertise with a long-term investment horizon across the full (private and public) life cycle. The portfolio is managed by RTW Investments, LP, a leading healthcare-focused investment firm dedicated to solving the most challenging unmet patient needs with a track record of supporting companies developing life-changing therapies.

KEY STATISTICS

\$941.9M

Ordinary NAV

\$2.92

NAV per ordinary share

\$2.52

Share price

+3.9%

MTD NAV per share return

\$811.9M

Market cap

\$0.8M

Daily traded volume (3m avg)

51

Number of positions >0.5%⁶

13.8%

Discount to NAV


HISTORICAL ANNUAL PER SHARE PERFORMANCE

YTD	NAV	Share Price	R2000 Biotech ¹	Nasdaq Biotech ²	AIC Sector ³
2026	19.1%	16.7%	31.6%	25.3%	3.8%
2025	35.7%	54.8%	44.6%	39.9%	18.4%
2024	-4.6%	-0.6%	2.5%	-1.4%	1.0%
2023	23.5%	16.0%	10.6%	3.7%	5.6%
2022	-10.2%	-32.0%	-31.3%	-10.9%	-12.4%
2021	-12.8%	-5.3%	-26.9%	-0.6%	-2.3%
2020	53.9%	37.2%	52.8%	25.7%	5.1%
2019	22.4%	31.7%	23.4%	12.1%	15.8%

PERFORMANCE CHARACTERISTICS

	MTD	1Y	3Y	5Y	ITD ⁴⁷	CAGR ⁵
NAV per ord share	3.9%	47.9%	81.9%	60.2%	181.1%	15.7%
Share Price	2.0%	79.4%	100.0%	29.2%	142.3%	13.3%
R2000 Biotech ¹	7.4%	88.4%	117.9%	20.3%	104.3%	10.6%
Nasdaq Biotech ²	10.5%	60.6%	83.7%	41.3%	123.8%	12.7%
AIC Sector ³	4.1%	16.8%	29.1%	9.7%	34.0%	4.4%

RTW BIO PERFORMANCE IN CONTEXT



PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS

1 Russell 2000 Biotechnology Index | 2 Nasdaq Biotechnology Index | 3 AIC Biotechnology & Healthcare Sector NAV TR (\$) per share | 4 Admission to the London Stock Exchange, 30/10/2019 | 5 CAGR measured from 30/10/2019 | 6 Previous factsheets displayed only “Core” positions; going forward, it will present all positions greater than 50bps exposure.

Top 10 Positions	Description	Lead Asset and Focus	% NAV	Public/Private	Clinical Stage ¹	Proximate Catalysts ¹
	Therapies for bladder cancer.	<i>Cretostimogene</i> Bladder cancer	7.5%	Public "CGON"	Phase 3	P3 data 3Q26
	Antibody-based medicines to treat autoimmune diseases.	<i>Vyvgart</i> Myasthenia gravis	6.1%	Public "ARGX"	Commercial	Vyvgart earnings
	Antibody treatments for psoriasis and related inflammatory conditions.	<i>ORKA-001</i> Psoriasis	5.2%	Public "ORKA"	Phase 2	PsO wk 28 data 3Q26
	RTW incubation, focused on underserved patients with cardiometabolic diseases.	<i>CX11</i> Obesity	4.8%	Private	Phase 3	Global P3 study early 27
	Cancers of the urinary tract, including the bladder and kidney lining.	<i>Zusduri</i> Bladder cancer	4.7%	Public "URGN"	Commercial	Zusduri + Jelmyto earnings
	Cancers driven by two of the most common cancer-causing genetic pathways.	<i>ERAS-0015 (RAS)</i> Solid tumours	4.0%	Public "ERAS"	Phase 1	P1 data 1H27
	RTW co-incubation, developing broad pipeline to treat obesity and related metabolic conditions.	<i>Ribupatide</i> Obesity	4.0%	Public "KLRA"	Phase 3	P3 data 2H27
	RTW-incubation developing treatment for Graves' disease and Thyroid Eye Disease.	<i>YB-101</i> Graves' + Thyroid Eye Disease	3.5%	Public "YARW"	Phase 2	P2 Graves' 2H27
	Precision medicine for the treatment of cancer.	<i>Vopimetostat</i> Pancreatic and lung cancers	3.5%	Public "TNGX"	Phase 1	P1/2 vopi+daraxon ESMO 4Q26
	Antibody therapeutics for cancer and immuno-inflammatory diseases	<i>XmAb819</i> Kidney cancer	3.5%	Public "XNCR"	Phase 1	P1 presentation ESMO 4Q26


% of NAV based on economic exposure

¹ Updated quarterly. Clinical data catalyst refers to lead asset

Sub-Portfolio Exposures ²		As of Month-End	
Public		90.0%	
Private		18.2%	
Royalties		1.7%	
Sub-Portfolio Attribution ²		MTD	YTD
Public		+4.6%	+22.8%
Private		+0.7%	+3.6%
Royalties		0.0%	+0.3%

Top Contributors ²		YTD
UroGen		+5.0%
Oruka		+3.6%
Yarrow Bioscience		+3.6%
Top Detractors ²		YTD
Ensoma		-1.7%
Insmed		-1.2%
Celcuity		-1.1%

² Public exposure/attribution was previously broken down between "Core" and "Other" public; they are now consolidated. Contributors & detractors also reflect the full portfolio. Sub-portfolio exposures reflect gross economic exposure as a percentage of NAV and could exceed 100%. Attribution for a position that was initially private and went public in the current year, is included in Public. Attribution is gross.



Exposures are calculated on positions greater than 0.5%, adjusted to sum to 100%, based on economic exposure. Except for development stage and subsector, exposures do not include royalty vehicles.

COMPANY UPDATE

On 19 August, RTW Bio appointed Jefferies International Limited as joint corporate broker alongside BofA Securities.

RTW Bio continued to make market purchases of its Ordinary Shares under the authority granted by shareholders at its Annual General Meeting in June 2026. RTW Bio repurchased 7.6 million shares (equivalent to \$14.7 million), over the twelve months to 31 August 2026. The discount to NAV at which RTW Bio's Ordinary Shares trade has closed from 28.9% to 13.8% over the same period.

SECTOR UPDATE

August was a strong month for biotech, with the NBI returning +10.5% and the Russell 2000 Biotech Index +7.4%. The sector recovered well from July's modest pullback, even as the probability of a near-term rate hike increased materially through the month. M&A has proven a more durable driver of sentiment than rate expectations: year-to-date deal value has reached approximately \$120 billion, a pace that reflects both the scale of upcoming patent expiries across large-cap pharma and the cash generation capacity that GLP-1 franchises now provide.

The IPO market continued to normalise. Five biotech IPOs priced in August, with an average return of approximately 53% from offer. Twenty biotech IPOs have now completed year-to-date, against eight for the whole of 2025, and aftermarket performance across the cohort remains healthy, with an average return of 68%.

August was also a notable month for FDA approvals. Revolution Medicines received approval for Rasonque in pancreatic cancer, and Replimune's Tudriqev was approved in refractory melanoma, two indications where patients have historically had very limited options. Moderna reported Phase 3 success for its personalised cancer vaccine in adjuvant melanoma. Taken together, these outcomes reinforce the case that oncology is entering a period of genuine, durable progress.

On FDA leadership, President Trump nominated Dr Heidi Overton as the next permanent commissioner, subject to Senate confirmation. Division heads are expected to continue the pro-innovation direction established under interim leadership. The sector has responded positively to the trajectory of change, and we are optimistic that a permanent appointment will bring further regulatory stability.

The broader backdrop supports our core views. Drug pricing policy uncertainty has largely resolved. Capital markets activity slowed in August as is typical in summer months, though reverse mergers remain an active and efficient route to the public markets. Innovation continues to accelerate, driven by the application of AI and the growing contribution of Chinese biotech science to the global pipeline. The number of emerging commercial-stage biotechs with rapidly growing revenues is increasing, and we expect this to attract a broader investor base over time.

PORTFOLIO UPDATE – AUGUST

On 4 August, private portfolio company Obsidian Therapeutics completed its previously announced reverse merger with Galera Therapeutics and began trading on Nasdaq under the ticker "OBX". The concurrent private financing of approximately \$350 million is expected to fund operations into the second half of 2028. RTW Bio first invested \$2.1 million in Obsidian's Series C in March 2024 and invested a further \$0.4 million in the PIPE financing immediately prior to the merger. Based on the closing share price on the first day of trading of \$34, the investment represented a 2.5x MOIC and a 170% uplift to carrying value. As at 31 August 2026, Obsidian represented 0.3% of RTW Bio's NAV.

On 12 August, private portfolio company Avere Therapeutics announced two concurrent private placements totalling \$820 million, to close immediately prior to its planned all-stock merger with NextCure Inc., with the combined company expected to trade on Nasdaq under "AVRX" by year-end. Avere is developing AVR-001, a once-weekly oral IL-23 receptor antagonist initially targeting psoriasis, with potential to expand into ulcerative colitis and Crohn's disease. RTW Bio first invested in Avere's Series A and, as at 31 August 2026, the position represented 0.3% of NAV.

On 19 August, BioMarin Pharmaceutical announced a definitive agreement to acquire private portfolio company Alesta Therapeutics for up to \$490 million, with \$275 million payable upfront for lead asset ALE1, an oral therapy in development for hypophosphatasia, a rare inherited bone disease. RTW Bio first invested in Alesta's Series A in December 2024 and participated again in September 2025, investing €2.4 million in aggregate. The upfront consideration represents a 41% uplift to RTW Bio's 31 July carrying value, adding \$1.6 million, or 0.2%, to NAV. This is the sixth acquisition from RTW Bio's portfolio announced in 2026.

Key RTW personnel for RTW Biotech Opportunities Ltd:

Roderick Wong, MD, Portfolio Manager; **Naveen Yalamanchi, MD**, Portfolio Manager; **Peter Fong, PhD**, RTW President; **Stephanie Sirota**, Chief Business Officer; **Woody Stileman**, Managing Director, Business Development; **Oliver Kenyon**, Senior Director, Business & Corporate Development; **Krishna McCune**, Director, Investor Relations

Board of Directors:

William Simpson, Chair; Chair of the Sustainability Committee; **Paul Le Page**, Chair of the Audit Committee; **William Scott**, Chair of the Nomination and Remuneration Committee; **Nicola Blackwood**, Senior Independent Director; **Stephanie Sirota**, Non-Executive Director

FUND INFORMATION

Structure: Closed-End Investment Fund	Financial Year End: 31 December	RTW Investments	
Domicile: Guernsey	Interim end: 30 June	Woody Stileman	+44 (0) 7717 417711
Listing: London Stock Exchange	Dividend policy: To be reinvested	Oliver Kenyon	+44 (0) 2079 596362
Launch date: 30 October 2019		Krishna McCune	+1 646 593 7998
SEDOL: BKTRRM2	Investment Manager: RTW Investments, LP	Jefferies International	
ISIN: GGO0BKTRRM22	Corporate Brokers: Deutsche Numis & BofA	Charles Stagg (Sales)	+44 (0) 2078 987118
Ticker: RTW	Distribution & IR Partner: Cadarn Capital	BofA	
Index inclusion: FTSE 250, FTSE All-Share		Edward Peel	+44 (0) 2076 281000
Currency: USD		Cadarn Capital	
Management fee: 1.25%		David Harris (Distribution)	+44 (0) 7368 883211
Performance fee: 20% with 8.0% hurdle		Lucy Clark (PR)	+44 (0) 7984 184461
Ongoing Charges Ratio: 1.74% (AIC methodology)			

DISCLAIMERS

This factsheet is not intended to offer or to promote the offer or transfer of the shares (the “shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. Persons” (“US persons”) as defined in Regulation S under the Securities Act of 1933 (the “1933 Act”).

No part of this factsheet may be reproduced in any manner without the written permission of the Company. The possession or distribution of this factsheet in certain jurisdictions may be restricted by law and persons into whose possession this factsheet comes should inform themselves about and observe any applicable restrictions. This factsheet does not constitute or form a part of any offer to sell, or any solicitation of any offer to purchase or otherwise acquire, securities in any jurisdiction. The securities described in this factsheet may not be eligible for sale in certain jurisdictions or suitable for all types of investors. The Company has not been and will not be registered under the US Investment Company Act of 1940 (the “Investment Company Act”) and the Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, transferred or delivered, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require the Company to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. This factsheet was prepared using the financial and other information available to the Company and RTW Investments, LP as at the date of this factsheet. The Shares are compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in EU Directive 2014/65/EU on markets and financial instruments, as amended (the “Target Market Assessment”). The Shares are traded on the Main Market of the London Stock Exchange. A key information document in respect of the Shares has been prepared by RTW Investments, LP and is available to investors at www.rtwbio.com. This information in this document is believed to be accurate but has not been audited by any third party. This factsheet may describe past performance, which cannot be relied on as a guide to future performance. This factsheet may include statements regarding investment strategies, individual securities and economic and market conditions; however, there can be no guarantee that such statements will prove to be correct. This factsheet may include expressions of opinions that are speculative in nature and should not be relied on as statements of fact. This factsheet may include forward-looking statements which are subject to known and unknown risks and uncertainties that may cause actual results and events to differ materially from those expressed in or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by words like “will seek”, “will target”, “believe”, “expect”, “intend”, or similar expressions. You should not place undue reliance on forward-looking statements. Each of the Company and RTW Investments, LP disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Neither the Company nor RTW Investments, LP accepts any liability for actions taken on the basis of the information provided in this factsheet. The information provided in this factsheet should not be considered a recommendation to buy, sell or hold any security.